View Item 

Show simple item record

Randomized Phase 2b Trial of Tofacitinib (CP‐690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year

dc.contributor.authorVincenti, F.en_US
dc.contributor.authorTedesco Silva, H.en_US
dc.contributor.authorBusque, S.en_US
dc.contributor.authorO’connell, P.en_US
dc.contributor.authorFriedewald, J.en_US
dc.contributor.authorCibrik, D.en_US
dc.contributor.authorBudde, K.en_US
dc.contributor.authorYoshida, A.en_US
dc.contributor.authorCohney, S.en_US
dc.contributor.authorWeimar, W.en_US
dc.contributor.authorKim, Y. S.en_US
dc.contributor.authorLawendy, N.en_US
dc.contributor.authorLan, S.‐p.en_US
dc.contributor.authorKudlacz, E.en_US
dc.contributor.authorKrishnaswami, S.en_US
dc.contributor.authorChan, G.en_US
dc.date.accessioned2012-09-05T14:46:14Z
dc.date.available2013-10-18T17:47:30Zen_US
dc.date.issued2012-09en_US
dc.identifier.citationVincenti, F.; Tedesco Silva, H.; Busque, S.; O’connell, P. ; Friedewald, J.; Cibrik, D.; Budde, K.; Yoshida, A.; Cohney, S.; Weimar, W.; Kim, Y. S.; Lawendy, N.; Lan, S.‐p. ; Kudlacz, E.; Krishnaswami, S.; Chan, G. (2012). "Randomized Phase 2b Trial of Tofacitinib (CPâ 690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year." American Journal of Transplantation 12(9). <http://hdl.handle.net/2027.42/93568>en_US
dc.identifier.issn1600-6135en_US
dc.identifier.issn1600-6143en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/93568
dc.publisherBlackwell Publishing Incen_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherTofacitiniben_US
dc.subject.otherKidneyen_US
dc.subject.otherCyclosporineen_US
dc.subject.otherRenal Functionen_US
dc.titleRandomized Phase 2b Trial of Tofacitinib (CP‐690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Yearen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationotherCharité Universitätsmedizin, Berlin, Germanyen_US
dc.contributor.affiliationotherUniversity of California, San Francisco, CAen_US
dc.contributor.affiliationotherHospital do Rim e Hipertensão, São Paulo, Brazilen_US
dc.contributor.affiliationotherStanford University, Stanford, CAen_US
dc.contributor.affiliationotherWestmead Hospital, Sydney, Australiaen_US
dc.contributor.affiliationotherNorthwestern University, Chicago, ILen_US
dc.contributor.affiliationotherHenry Ford Hospital, Detroit, MIen_US
dc.contributor.affiliationotherRoyal Melbourne Hospital, Melbourne, Australiaen_US
dc.contributor.affiliationotherErasmus Medisch Centrum, Rotterdam, The Netherlandsen_US
dc.contributor.affiliationotherSeoul National University College of Medicine, Seoul, Koreaen_US
dc.contributor.affiliationotherPfizer Inc., Groton, CTen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/93568/1/j.1600-6143.2012.04127.x.pdf
dc.identifier.doi10.1111/j.1600-6143.2012.04127.xen_US
dc.identifier.sourceAmerican Journal of Transplantationen_US
dc.identifier.citedreferenceFlechner SM. Sirolimus in kidney transplantation indications and practical guidelines: De novo sirolimus‐based therapy without calcineurin inhibitors. Transplantation 2009; 87: S1 – S6.en_US
dc.identifier.citedreferenceNankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326 – 2333.en_US
dc.identifier.citedreferenceMeier‐Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378 – 383.en_US
dc.identifier.citedreferenceOpelz G, Dohler B. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009; 87: 795 – 802.en_US
dc.identifier.citedreferenceKaplan B, Schold JD, Meier‐Kriesche HU. Long‐term graft survival with neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol 2003; 14: 2980 – 2984.en_US
dc.identifier.citedreferenceGoldfarb‐Rumyantzev AS, Smith L, Shihab FS, et al. Role of maintenance immunosuppressive regimen in kidney transplant outcome. Clin J Am Soc Nephrol 2006; 1: 563 – 574.en_US
dc.identifier.citedreferenceVincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept‐based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535 – 546.en_US
dc.identifier.citedreferenceHjelmesaeth J, Hartmann A, Leivestad T, et al. The impact of early‐diagnosed new‐onset post‐transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006; 69: 588 – 595.en_US
dc.identifier.citedreferenceYates PJ, Nicholson ML. The aetiology and pathogenesis of chronic allograft nephropathy. Transpl Immunol 2006; 16: 148 – 157.en_US
dc.identifier.citedreferenceGaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody‐mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68 – 74.en_US
dc.identifier.citedreferenceGaston RS. Chronic calcineurin inhibitor nephrotoxicity: Reflections on an evolving paradigm. Clin J Am Soc Nephrol 2009; 4: 2029 – 2034.en_US
dc.identifier.citedreferenceNankivell BJ, Fenton‐Lee CA, Kuypers DR, et al. Effect of histological damage on long‐term kidney transplant outcome. Transplantation 2001; 71: 515 – 523.en_US
dc.identifier.citedreferenceVincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506 – 1514.en_US
dc.identifier.citedreferenceHariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post‐transplant renal function in the first year predicts long‐term kidney transplant survival. Kidney Int 2002; 62: 311 – 318.en_US
dc.identifier.citedreferenceGill JS, Tonelli M, Mix CH, Pereira BJ. The change in allograft function among long‐term kidney transplant recipients. J Am Soc Nephrol 2003; 14: 1636 – 1642.en_US
dc.identifier.citedreferenceSilva HT, Jr., Yang HC, Abouljoud M, et al. One‐year results with extended‐release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007; 7: 595 – 608.en_US
dc.identifier.citedreferenceEkberg H, Tedesco‐Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562 – 2575.en_US
dc.identifier.citedreferenceNankivell BJ, Gruenewald SM, Allen RD, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683 – 1689.en_US
dc.identifier.citedreferenceLevey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461 – 470.en_US
dc.identifier.citedreferenceRacusen LC, Colvin RB, Solez K, et al. Antibody‐mediated rejection criteria—An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708 – 714.en_US
dc.identifier.citedreferenceBusque S, Leventhal J, Brennan DC, et al. Calcineurin‐inhibitor‐free immunosuppression based on the JAK inhibitor CP‐690,550: A pilot study in de novo kidney allograft recipients. Am J Transplant 2009; 9: 1936 – 1945.en_US
dc.identifier.citedreferenceWeir MR, Diekmann F, Flechner SM, et al. mTOR inhibition: The learning curve in kidney transplantation. Transpl Int 2010; 23: 447 – 460.en_US
dc.identifier.citedreferenceVincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282 – 1287.en_US
dc.identifier.citedreferenceSrinivas TR, Schold JD, Guerra G, Eagan A, Bucci CM, Meier‐Kriesche HU. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007; 7: 586 – 594.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1600-6143.2012.04127.x.pdf
Size:
688.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.